Forum Posts

omar faruk
Jul 31, 2022
In Elder Care Forum
From the known structure, the new coronavirus has a large RNA genome, the replication process is prone to errors, and it needs to rely on its own proofreading mechanism, so the mutation speed is relatively slow . SARS in 2012, MERS in 2012) mutated at a similar rate. Although this rate is not half as slow as the mutation rate of the influenza virus, influenza is already a virus that we can produce a vaccine against every year. Therefore, "vaccine development" is more critical than drugs. According to the latest information (normal update) released by the World Health Organization (WHO) on June 2, 10 candidate vaccines have entered the clinical trial stage, and 123 candidate vaccines are in the pre-clinical trial stage. Judging from whatsapp database these 10 recent trials that are most likely to successfully develop a vaccine, there are few vaccine industry leaders (such as Pfizer Pfizer, MSD MSD, GlaxoSmithKline GSK, Sanofi and Johnson & Johnson), these large The company has not been as aggressively developing a vaccine as had hoped. Brad Loncar, biotech investor and CEO of Loncar Investments in the United States, pointed out: "It is very difficult to successfully develop a preventive vaccine or treatment to solve a public health crisis, especially with a lot of time and money costs." It can be seen that vaccine development is easier said than done, amazing R&D costs, risks and uncertainties make the leaders dare not bear it, so there is a lack of interest . However, given the high threshold of vaccine research and development, there are still countries and companies willing to invest. They are just looking at its effectiveness in publicity, building international reputation, raising more investment opportunities, and the potential to improve the economic downturn. .
It Will Be More and More Difficult to Rely on Experience to Make Ends Meet Learning in the Past  content media
0
0
2
 

omar faruk

More actions